Dr. Turcotte is a surgeon-scientist with bench-to-bedside expertise in solid cancer immunology and immunotherapy. He is an associate professor at the Université de Montréal, a hepatopancreatobiliary (HPB) surgical oncologist and scientist at the Centre hospitalier de l’Université de Montréal (CHUM).
He completed his general surgery training and a Masters in cancer immunology at Université de Montréal. He did his post-doctoral research training in cancer immunotherapy at the National Cancer Institute, Maryland, in the laboratory of Dr. Steven A. Rosenberg. He also completed a fellowship in HBP cancer surgery at the Memorial Sloan Kettering Cancer Center in New York.
He is leading the CHUM adoptive T cell immunotherapy program. He is the principal investigator of the two first T cell immunotherapy trials to be conducted at CHUM. His translational research program focuses on characterizing therapeutically actionable features of T lymphocytes infiltrating solid cancers to improve cancer immunotherapy efficacy.
In 2017, he was nominated the Université de Montréal Roger Des Groseillers Research Chair in HBP Surgical Oncology and received an Innovator Award from the Canadian Association of General Surgeons. His research program is supported by Biotherapeutics for Cancer Treatment (BioCanRx), the largest pan-Canadian network supporting cancer immunotherapy. His publications have been cited more than 3600 times.
